Kura Oncology highlights ziftomenib preclinical activity, menin binding profile in Blood publication
KURA•Clinical development and approved setting
Ziftomenib was cleared by the FDA in 2025 for adults with relapsed or refractory NPM1-mutated AML with no satisfactory alternatives.
Kura is advancing combination studies across the AML treatment continuum, targeting additional molecularly defined patient groups beyond its approved setting.
Blood publication details ziftomenib profile
Kura Oncology highlighted a new Blood publication detailing the discovery and preclinical profile of its menin inhibitor ziftomenib.
Results were already published; the work showed broad preclinical anti-leukemia activity across genetically defined models.
Resistance-linked mutations and binding profile
The study also indicated activity against some resistance-linked MEN1 mutations, supporting a differentiated binding profile versus other menin inhibitors.
